Baidu
map

Nature Medicine:一次血检能预测多种疾病?测了上万份样本 新研究实现概念验证

2019-12-04 佚名 医学新视点

根据《自然·医学》最新发表的一项来自剑桥大学(University of Cambridge)、加州大学旧金山分校(University of California San Francisco)和美国SomaLogic生物技术公司的合作研究,通过一次血液检测进行大规模蛋白质分析,有望预测多种疾病和风险因素。

不同疾病都有各自针对性的筛查和诊断方式,有时还需要做多项检测。将来,这也许能得到简化。

根据《自然·医学》最新发表的一项来自剑桥大学(University of Cambridge)、加州大学旧金山分校(University of California San Francisco)和美国SomaLogic生物技术公司的合作研究,通过一次血液检测进行大规模蛋白质分析,有望预测多种疾病和风险因素。

我们的身体中有大约30,000种不同的蛋白质。其中一些蛋白质能够带着“指令”被分泌进入血液,参与调节影响健康的生化过程,激素、细胞因子和生长因子都属于这类蛋白质。另一些则在细胞损伤或死亡时渗漏进入血液。无论通过哪种方式进入血液,这两大类蛋白质都能反映我们的健康状况和疾病风险。很多蛋白质还同时和多种健康状况有关,比如调节食欲和新陈代谢的瘦素,对于预测人体脂肪、内脏脂肪、身体活动都有帮助。

那么,通过血浆蛋白,一次性同时评估多种疾病风险可行吗?想法很美好,但一直尚未得到科学的检验。

在这项概念验证研究中,研究团队检测了17,000名受试者的血浆样本,共涉及约5000种蛋白质检测。蛋白质检测技术用到了核酸适配体,这是一种能够与靶蛋白结合的DNA片段。就像一把锁配一把钥匙,通常只有特定的DNA片段会与特定的蛋白质结合。使用现有的基因测序技术,研究人员可以检测核酸适配体,从而确定相应的蛋白质及其浓度。

接下来,结合预先记录的受试者的临床指标数据,研究团队针对11种不同的健康指标开发并验证了蛋白质检测的模型,包括肝脂肪、肾功能、体脂率、内脏脂肪量、瘦体重、心肺健康、身体活动、饮酒、吸烟、糖尿病风险和原发性心血管事件风险。

结果显示,这一模型对不同健康状况的预测能力各不相同,比如预测体脂率的准确性更高,对于心血管风险,则准确度中等。但研究人员介绍,相较于基于传统风险因素的疾病评估模型,这种蛋白质模型的预测能力要么更好,要么有望成为更便捷、更便宜的替代方案。

研究团队还补充介绍了蛋白质检测和基因组测序的区别。基因组通常是不变的,但蛋白质组会随着时间而变化,比如在人们变胖、体育活动量有所增减、或吸烟饮酒时,体内蛋白质的组成都会受到影响,因此,通过检测蛋白质,还有可能追踪一生中个体健康状况的变化。

作者之一,剑桥大学Claudia Langenberg博士说,“血液中循环的蛋白质是我们基因组成以及其他许多因素的表现,包括生活方式和即便尚未被诊断出来的疾病。这就是为什么蛋白质能很好反映我们当前和未来健康状况,而且有潜力改善我们对不同疾病的预测能力。”

研究团队表示,随着技术的进步和成本的降低,一次血检就进行全面健康评估,有望成为临床服务中的常规方法。加州大学旧金山分校医学教授Peter Ganz博士对此充满期待,“希望将来有一天,个体化诊疗得到更多应用时,我们回过头看,能把这项研究视为关键里程碑。”

原始出处:

Stephen A. Williams, et al. Plasma protein patterns as comprehensive indicators of health, Nature Medicine. Nature Medicine, 2019, 10.1038/s41591-019-0665-2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2020-11-02 zhzhxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2020-02-26 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2020-03-06 一叶知秋
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
    2020-02-29 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1669412, encodeId=9a5516694127b, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Nov 02 07:31:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884029, encodeId=b51018840298a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 26 08:31:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773826, encodeId=10291e7382680, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Mar 06 06:31:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859012, encodeId=11fd1859012da, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Feb 29 07:31:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447037, encodeId=cf15144e03788, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577695, encodeId=76e515e7695e7, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610159, encodeId=d24216101596d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Dec 06 12:31:00 CST 2019, time=2019-12-06, status=1, ipAttribution=)]

相关资讯

提升体验 捍卫品质 美年大健康实现血液检测全程追踪管理

随着消费者对医疗服务要求的提升,医疗机构也进一步向着“以人为本”的管理和服务理念转变,注重医疗服务品质和内涵提升。近期,为了进一步解决消费者在体检中遇到的实际问题,提升医疗服务品质,美年大健康产业(集团)有限公司(以下简称“美年大健康”)打造了血液样本追踪系统,消费者只需简单通过扫描导引单上的二维码,即可及时跟踪了解血液样本的运转及检测状况。 “血液样本追踪系统”页面 消费者来体检中心体检的时候

日本研发出用一滴血检测多种癌症的技术

据《日本经济新闻》6月11日报道,日本东丽将在2019年内针对只用一滴血就能发现各种癌症的检测方法,向日本厚生劳动省申请制造销售许可。如果被选为优先审查对象,很可能最早在2020年获批。该方法有望尽早发现胰腺癌等癌症。

Anesth Analg:术前常规血液检查时机与术后30天并发症发生率及死亡率的关系

ASA分级I-II级的患者,其实验室检查延长至术前2个月并不增加术后30天的并发症发生风险和死亡风险,这表明并不需要在术前短时间内复查其实验室检查结果。

PNAS:“人未工作身先累”?斯坦福科学家为十年患病儿子,找出“慢性疲劳综合征”的科学证据

“人未工作身先累?”的症状通常都被认为是逃避工作的“懒惰”,而头痛、记忆力减退也被认为是为“懒惰”找的借口,这种情况让患有慢性疲劳症的人感觉太委屈。

Communications Biology:血液检测诊断“恶性脑瘤”,侵入性更小、结果更快

胶质母细胞瘤(Glioblastoma,GBM),原发性脑肿瘤的一种,占所有脑恶性肿瘤的16%,死亡率极高。对于这类疾病的诊断和治疗,就是和时间进行赛跑。

Nat Med:滴血验病!这项血液检测揭晓肾脏和心血管疾病危险系数

格拉斯哥大学的研究者在《Nature Medicine》杂志上,提出了一项精确而简单的血液测试,可以衡量肾脏和心血管疾病风险。

Baidu
map
Baidu
map
Baidu
map